Alberto Álvarez‐Larrán

Author

Also Known As

A Alvarez-Larrán, A Álvarez-Larrán, A Álvarez-Larrán, A. ALVAREZ-LARRAN, A. Alvarez-Larran, A. Alvarez-Larrán, A. Alvarez‐Larran, A. Alvarez‐Larrán, A. Álvarez-Larrán, Alberto Alvarez-Larran

249

Publications

6.1K

Citations

H-Index

100

Concepts

All Affiliations

Hospital Clínic de Barcelona Hospital Del Mar Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Hospital Clínico Universitario de Valencia Universitat de Barcelona

AÁ

About

Alberto Álvarez‐Larrán is an author at Hospital Clínic de Barcelona specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	50	2.2K
2	Public Health	8	8	520
3	Health Sciences	7	7	267
4	Engineering	2	2	91
5	Allergy	2	2	57

Alberto Álvarez‐Larrán

Publications

Citations

H-Index

Page 1

	Year	Citations
Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Eduardo Arellano‐Rodrigo, Alberto Álvarez‐Larrán, Joan Carles Reverter, PubMed	2006	275
Thrombosis in primary myelofibrosis: incidence and risk factors Tiziano Barbui, Alessandra Carobbio, Francisco Cervantes, Blood	2009	256
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia Alberto Álvarez‐Larrán, Francisco Cervantes, Arturo Pereira, Blood	2010	229
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera Alberto Álvarez‐Larrán, Arturo Pereira, Francisco Cervantes, Blood	2011	221
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients Francisco Cervantes, Alberto Álvarez‐Larrán, Carme Talarn, British Journal of Haematology	2002	159
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation Alberto Álvarez‐Larrán, Arturo Pereira, Paola Guglielmelli, Haematologica	2016	145
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and <i>JAK</i>2 V617F allele burden Eduardo Arellano‐Rodrigo, Alberto Álvarez‐Larrán, Joan Carles Reverter, American Journal of Hematology Jak2 MutationImmunologyPlatelet PathobiologyInflammationThrombosis	2008	135
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients Alberto Álvarez‐Larrán, Francisco Cervantes, Beatríz Bellosillo, Leukemia ThrombopoiesisThrombosisVenous ThrombosisVascular EventsCardiovascular Disease	2007	126
Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long‐term results in 30 patients Francisco Cervantes, Alberto Álvarez‐Larrán, A Domingo, British Journal of Haematology	2005	123
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients Valerio De Stefano, Alessandro M. Vannucchi, Marco Ruggeri, Blood Cancer Journal	2016	98

Page 1